NeuroSearch, GlaxoSmithKline Halt Development Of NS2389

The antidepressant drug development alliance between Danish firm NeuroSearch A/S and partner GlaxoSmithKline plc has hit a bump that will delay progress by several years. The two companies have decided to discontinue development of the neurotransmitter reuptake inhibitor NS2389, which had been in Phase II clinical trials. (BioWorld International)